Article
Prediction of key genes and pathways involved in trastuzumab-resistant gastric cancer
22 Aug 2018
Abstract excerpt
BACKGROUND: Trastuzumab has been prevailingly accepted as a beneficial treatment for gastric cancer (GC) by targeting human epidermal growth factor receptor 2 (HER2)-positive. However, the therapeutic resistance of trastuzumab remains a major obstacle, restricting the therapeutic efficacy. Therefore, identifying potential key genes and pathways is crucial to maximize the overall clinical benefits. METHODS: The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
